Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: The Japan Morning Surge 1 study

Journal of Hypertension

Volumn 26, Issue 10, 2008, Pages 1928-1934

  Matsui, Yoshio ^a   Eguchi, Kazuo ^a   Shibasaki, Seiichi ^a   Ishikawa, Joji ^a,b   Hoshide, Satoshi ^a   Pickering, Thomas G ^a   Shimada, Kazuyuki ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

atenolol; B type natriuretic peptide; brachial pulse pressure; central pulse pressure; doxazosin; pulse pressure amplification

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DOXAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART RATE; HEART WORK; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; CAROTID ARTERY; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; JAPAN; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ATENOLOL; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BRACHIAL ARTERY; CAROTID ARTERIES; CASE-CONTROL STUDIES; DOXAZOSIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN;

EID: 58149121010     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32830dd0b0     Document Type: Article

References (39)

1. Glynn RJ, Chae CU, Guralnik JM, Taylor JO, Hennekens CH. Pulse pressure and mortality in older people. Arch Intern Med 2000; 160:2765- 2772.
2. Vaccarino V, Berger AK, Abramson J, Black HR, Setaro JF, Davey JA, Krumholz HM. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol 2001; 88:980-986.
3. Boutouyrie P, Bussy C, Lacolley P, Girerd X, Laloux B, Laurent S. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100:1387-1393.
4. Waddell TK, Dart AM, Medley TL, Cameron JD, Kingwell BA. Carotid pressure is a better predictor of coronary artery disease severity than brachial pressure. Hypertension 2001; 38:927-931.
5. Philippe F, Chemaly E, Blacher J,Mourad JJ, Dibie A, Larrazet F, et al. Aorticpulse pressure and extent of coronary artery disease in percutaneous transluminal coronary angioplasty candidates. Am J Hypertens 2002; 15:672-677.
6. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Styczkiewicz M, et al. Ascending aortic, but not brachial blood pressure-derived indices are related to coronary atherosclerosis. Atherosclerosis 2004; 176:151-155.
7. Danchin N, Benetos A, Lopez-Sublet M, Demicheli T, Safar M, Mourad JJ, ESCAPP Investigators. Aortic pulse pressure is related to the presence and extent of coronary artery disease in men undergoing diagnostic coronary angiography: a multicenter study. Am J Hypertens 2004; 17:129-133.
8. Sharman JE, Fang ZY, Haluska B, Stowasser M, Prins JB, Marwick TH. Left ventricular mass in patients with type 2 diabetes is independently associated with central but not peripheral pulse pressure. Diabetes Care 2005; 28:937-939.
9. Sharman JE, Haluska BA, Fang ZY, Prins JB, Marwick TH. Association of arterial wave properties and diastolic dysfunction in patients with type 2 diabetes mellitus. Am J Cardiol 2007; 99:844-848.
10. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50:197-203.
11. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
12. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, London GM. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735-738.
13. Chirinos JA, Zambrano JP, Chakko S, Veerani A, Schob A, Perez G, Mendez AJ. Relation between ascending aortic pressures and outcomes in patients with angiographically demonstrated coronary artery disease. Am J Cardiol 2005; 96:645-648.
14. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME, REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22:1623-1630.
15. Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ. In?uence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002; 103:493-499.
16. Davies J, Carr E, Band M, Morris A, Struthers A. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? J Renin Angiotensin Aldosterone Syst 2005; 6:151-153.
17. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006; 19:214-219.
18. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26:351-356.
19. Eguchi K, Matsui Y, Shibasaki S, Ishikawa J, Hoshide S, Ishikawa S, et al. Changes in self-monitored pulse pressure correlate with improvements in B-type natriuretic Peptide and urinary albumin in treated hypertensive patients. Am J Hypertens 2007; 20:1268-1275.
20. Ishikawa J, Hoshide S, Shibasaki S, Matsui Y, Kabutoya T, Eguchi K, et al. Japan morning surge-1 (JMS-1) study: protocol description. Hypertens Res 2006; 29:153-159.
21. Verbeke F, Segers P, Heireman S, Vanholder R, Verdonck P, Van Bortel LM. Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure ampli?cation. Hypertension 2005; 46:244-248.
22. Matsui Y, Kario K, Ishikawa J, Eguchi K, Hoshide S, Shimada K. Reproducibility of arterial stiffness indices (pulse wave velocity and augmentation index) simultaneously ssessed by automated pulse wave analysis and their associated risk factors in essential hypertensive patients. Hypertens Res 2004; 27:851-857.
23. Sugawara J, Komine H, Hayashi K, Maeda S, Matsuda M. Relationship between augmentation index obtained from carotid and radial artery pressure waveforms. J Hypertens 2007; 25:375-381.
24. Asmar RG, London GM, O'Rourke ME, Safar ME, REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave re?ections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38:922-926.
25. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17:118-123.
26. Hirata K, Vlachopoulos C, Adji A, O'Rourke MF. Bene?ts from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery? J Hypertens 2005; 23:551-556.
27. Jiang XJ, O'Rourke MF, Zhang YQ, He XY, Liu LS. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 2007; 25:1095-1099.
28. Wilkinson IB, MacCallum H, Hupperetz PC, van Thoor CJ, Cockcroft JR, Webb DJ. Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol 2001; 530:541-550.
29. Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor lockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension 2003; 41:1253-1258.
30. Nichols WW, O'Rourke MF. Properties of the arterial wall: theory. In: NicholsWW,O'Rourke MF, editors. McDonald's blood ?ow in arteries, 5th ed. London, United Kingdom: Hodder Arnold; 2005.
31. Lubien E,DeMaria A, Krishnaswamy P,Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105:595-601.
32. Wilner KD, Ziegler MG. Effects of alpha 1 inhibition on renal blood ?ow and sympathetic nervous activity in systemic hypertension. Am J Cardiol 1987; 59:82G-86G.
33. The ALLHAT Of?cers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000; 283:1967-1975.
34. OlsenMH,Wachtell K, Tuxen C, FossumE, Bang LE, HallC, et al.Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005; 23:1083-1090.
35. Hashimoto J, Imai Y, O'Rourke MF. Monitoring of antihypertensive therapyfor reduction in left ventricular mass. Am J Hypertens 2007; 20:1229-1233.
36. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22:1597-1604.
37. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322.
38. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28:22-30.
39. Al?e J, Waisman GD, Galarza CR, Camera MI. Contribution of stroke volume to the change in pulse pressure pattern with age. Hypertension 1999; 34 (Part 2):808-812.